Mechanism study of isoflavones as an anti-retinoblastoma progression agent

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Isoflavones are bioactive compounds found in soy with known anticancer properties.
• Retinoblastoma is a malignant tumor of the retina, primarily affecting young children.
• Investigating natural compounds for cancer treatment is a significant area of research.

Purpose of the Study:

• To evaluate the anticancer effects of isoflavones on human retinoblastoma Y79 cells.
• To elucidate the molecular mechanisms underlying isoflavone-induced cell cycle arrest.
• To assess the efficacy of isoflavones against retinoblastoma both in vitro and in vivo.

Main Methods:

• MTT assay to determine cell viability and IC50 values.
• Flow cytometry to analyze cell cycle progression (G1/S phase).
• Western blot analysis to assess protein expression (mTOR pathway, cyclin E1).
• In vivo studies using a xenograft mouse model.

Main Results:

• Isoflavones demonstrated significant cytotoxicity against retinoblastoma Y79 cells (IC50 = 1.23 ± 0.42 μmol/l).
• Isoflavones induced G1/S phase cell cycle arrest.
• Inhibition of the mammalian target of rapamycin (mTOR) pathway and downregulation of cyclin E1 were observed.
• Isoflavones suppressed retinoblastoma tumor growth in vivo, with similar molecular changes.

Conclusions:

• Isoflavones exhibit potent anti-retinoblastoma activity in vitro and in vivo.
• The anticancer effects are mediated through the inhibition of the mTOR pathway and subsequent downregulation of cyclin E1, leading to G1 phase arrest.
• Isoflavones represent a promising therapeutic candidate for retinoblastoma treatment.